These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 21069944)

  • 1. Efficacy of sorafenib, molecular targeting drug, for advanced hepatocellular carcinoma.
    Kuzuya T; Tsuchiya K; Izumi N
    Gan To Kagaku Ryoho; 2010 Oct; 37(10):1883-86. PubMed ID: 21069944
    [No Abstract]   [Full Text] [Related]  

  • 2. [Use of sorafenib (Nexavar) in the treatment of hepatocellular carcinoma: PRODIGE AFEF recommendations].
    Boige V; Barbare JC; Rosmorduc O;
    Gastroenterol Clin Biol; 2008 Jan; 32(1 Pt. 1):3-7. PubMed ID: 18341970
    [No Abstract]   [Full Text] [Related]  

  • 3. Sorafenib in hepatocellular carcinoma: separating the hype from the hope.
    Kelley RK; Venook AP
    J Clin Oncol; 2008 Dec; 26(36):5845-8. PubMed ID: 19029408
    [No Abstract]   [Full Text] [Related]  

  • 4. Sorafenib: delivering a targeted drug to the right targets.
    Flaherty KT
    Expert Rev Anticancer Ther; 2007 May; 7(5):617-26. PubMed ID: 17492926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan.
    Kudo M; Ueshima K
    Oncology; 2010 Jul; 78 Suppl 1():154-66. PubMed ID: 20616599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Positioning and indication of sorafenib in the treatment algorithm and real practice setting: Western and eastern approach--Asian perspective.
    Lee JM; Han KH
    Oncology; 2010 Jul; 78 Suppl 1():167-71. PubMed ID: 20616600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic treatment of hepatocellular carcinoma: dawn of a new era?
    Zhu AX
    Ann Surg Oncol; 2010 May; 17(5):1247-56. PubMed ID: 20405329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sorafenib: new indication. For some patients with liver cancer.
    Prescrire Int; 2009 Apr; 18(100):59. PubMed ID: 19585718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma.
    Zhu AX
    Expert Opin Investig Drugs; 2010 May; 19(5):663-72. PubMed ID: 20367287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib.
    Yau T; Pang R; Chan P; Poon RT
    Expert Opin Pharmacother; 2010 Sep; 11(13):2187-98. PubMed ID: 20707757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDA approves sorafenib for patients with inoperable liver cancer.
    Lang L
    Gastroenterology; 2008 Feb; 134(2):379. PubMed ID: 18242200
    [No Abstract]   [Full Text] [Related]  

  • 12. Sorafenib improves the survival of patients with advanced hepatocellular carcinoma: a meta-analysis of randomized trials.
    Zhang T; Ding X; Wei D; Cheng P; Su X; Liu H; Wang D; Gao H
    Anticancer Drugs; 2010 Mar; 21(3):326-32. PubMed ID: 20016366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hepatocellular carcinoma management in the era of sorafenib].
    Rosmorduc O
    Gastroenterol Clin Biol; 2009 Apr; 33(4):327-33. PubMed ID: 19321281
    [No Abstract]   [Full Text] [Related]  

  • 14. Treating hepatocellular carcinoma with sorafenib in liver transplant patients: an initial experience.
    Saidi RF; Shah SA; Rawson AP; Grossman S; Piperdi B; Bozorgzadeh A
    Transplant Proc; 2010 Dec; 42(10):4582-4. PubMed ID: 21168742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver transplantation in a patient treated by sorafenib for hepatocellular carcinoma.
    Borentain P; Gregoire E; Hardwigsen J; Garcia S; Durieux O; Le Treut YP; Gérolami R
    Clin Res Hepatol Gastroenterol; 2011 Mar; 35(3):234-6. PubMed ID: 21345761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial.
    Rimassa L; Santoro A
    Expert Rev Anticancer Ther; 2009 Jun; 9(6):739-45. PubMed ID: 19496710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Signaling pathway and molecular-targeted therapy for hepatocellular carcinoma.
    Kudo M
    Dig Dis; 2011; 29(3):289-302. PubMed ID: 21829020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib.
    Cabibbo G; Rolle E; De Giorgio M; Genco C; Pressiani T; Spada F; Sacco R;
    Expert Rev Anticancer Ther; 2011 Dec; 11(12):1807-16. PubMed ID: 22049974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sorafenib therapy in patients with advanced hepatocellular carcinoma in advanced liver cirrhosis.
    Schütte K; Zimmermann L; Bornschein J; Csepregi A; Rühl R; Ricke J; Malfertheiner P
    Digestion; 2011; 83(4):275-82. PubMed ID: 21282952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sorafenib as a feasible therapeutic option in haemophiliacs with hepatocellular carcinoma.
    Lapecorella M; Napolitano M; Tudini M; Bruera G; Lucchesi A; Giordano AV; Mariani G; Ricevuto E
    Haemophilia; 2010 Jan; 16(1):185-7. PubMed ID: 19804385
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.